OXIDATION OF QUINIDINE BY HUMAN-LIVER CYTOCHROME-P-450
- 1 September 1986
- journal article
- research article
- Vol. 30 (3) , 287-295
- https://doi.org/10.1016/s0026-895x(25)10372-6
Abstract
The anti-arrhythmic quinidine has been reported to be a competitive inhibitor of the catalytic activities of human liver P-450DB, including sparteine .DELTA.2-oxidation and bufuralol 1''-hydroxylation, and we confirmed the observation that submicromolar concentrations are strongly inhibitory. Human liver microsomes oxidize quinidine to the 3-hydroxy (Km 4 .mu.M) and N-oxide (Km 33 .mu.M) products, consonant with in vivo observations. Both bufuralol and sparteine inhibited microsomal quinidine 3-hydroxylation. Liver microsomes prepared from DA strain rats showed a relative deficiency in quinidine 3-hydroxylase activity in females compared to males. These observations might suggest that quinidine oxidation is catalyzed by the same P-450 forms that oxidize debrisoquine, bufuralol, and sparteine; i.e., rat P-450UT-H and P-450DB. However, neither of these two purified enzymes catalyzed quinidine 3-hydroxylation, and anti-P-450UT-H, which strongly inhibits human liver microsomal bufuralol 1''-hydroxylation, did not substantially inhibit quinidine 3-hydroxylation or N-oxygenation, P-450MP, the human S-mephenytoin 4-hydroxylase, also does not appear to oxidize quinidine but P-450NF, the human nifedipine oxidase, does. Anti-P-450NF inhibited > 95% of the 3-hydroxylation and > 85% of the N-oxygenation of quinidine in several microsomal samples. Quinidine inhibited microsomal nifedipine oxidation and, in a series of human liver samples, rates of nifedipine oxidation were correlated with rates of quinidine oxidation. Thus, quinidine oxidation appears to be catalyzed primarily by P-450NF and not by P-450DB. Quinidine binds 2 orders of magnitude more tightly to P-450DB, which does not oxidize it, than to P-450NF, the major enzyme involved in its oxidation. The substrate specificity of human P-450NF is discussed further in terms of its regioselective oxidations of complex molecules including quinidine, aldrin, benzphetamine, cortisol, testosterone and androstenedione, estradiol, and several 2,6-dimethyl-1,4-dihydropyridines.This publication has 15 references indexed in Scilit:
- Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolismBiochemistry, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Purification and characterization of six cytochrome P-450 isozymes from human liver microsomesBiochemistry, 1983
- Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or .beta.-naphthoflavoneBiochemistry, 1982
- Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strainsJournal of Pharmacy and Pharmacology, 1981
- Quinidine-Rifampin InteractionNew England Journal of Medicine, 1981
- Determination of bufuralol and its major metabolites in plasma by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1980
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Interaction of Quinidine with Anticonvulsant DrugsNew England Journal of Medicine, 1976
- The Carbon Monoxide-binding Pigment of Liver MicrosomesJournal of Biological Chemistry, 1964